Ranbaxy announces launch of Atorvastatin, generic Lipitor®, in the U.S.
Forest Laboratories and Nycomed Receive Complete Response Letter for Roflumilast
Saudi Food and Drug Authority Suspends The Authorisation of Rosiglitazone (Avandia®)
Novel Drug for Chronic Management of Hyperuricemia in Gout Patients
FDA Grants IBsolvMIR Orphan Drug designation in the treatment of diabetes patients in the U.S.
Orphan Drug Designation for the treatment of patients with atypical Hemolytic Uremic Syndrome (aHUS)
Schering-Plough Announces European Filing of SYCREST(R) (asenapine)
More Articles ...
- HemCon Announces Further Successful Results from Live Nail Infection Anti-Fungal Study
- New Non-Drowsy CLARITIN(R) Liqui-Gels(R) Now Available
- U.S. FDA Issues Complete Response Letter for SAPHRIS(TM)
- Forest Laboratories, Inc. Announces Amendment to Bystolic(TM) (nebivolol) Agreement
- Trasylol® - One Thousand Lives A Month
- Pharmion and MethylGene Announce U.S. Orphan Drug Designation
- Pharmion Submits European Marketing Authorization Application (MAA) for Vidaza(R)